SAb Biotherapeutics is a clinical-stage biopharmaceutical company that is revolutionizing immunotherapies. Their focus is on developing powerful and proprietary immunotherapeutic polyclonal human antibodies to treat and prevent infectious diseases, immune and autoimmune disorders, and oncology. They harness the body's natural defense system to address infectious diseases, outbreaks, and pandemics, as well as diseases that have significant mortality and health impacts on immunocompromised patients.

SAb's groundbreaking drug development platform, DiversitAb™, allows them to generate large quantities of specifically targeted, high-potency polyclonal antibodies without relying on convalescent plasma or human donors. This platform is made possible through their proprietary Transchromosomic cows (Tc Bovine™), which produce fully-human, highly-efficacious polyclonal antibodies. These cows are a key component of SAb's novel platform, designed to tackle the emergence, mutation, and diversity of modern health challenges.

With advanced engineering and cutting-edge technologies refined over nearly two decades, SAb Biotherapeutics is paving the way for a new era in immunotherapies. They are dedicated to making a significant impact in the field of healthcare by leveraging the power of the natural human immune system